Fate Therapeutics Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cowen Sees High Probability of Positive Data ASH at from Fate Therapeutics (FATE)
November 4, 2015 7:12 AM ESTCowen analyst Boris Peaker reiterated an Outperform rating on Fate Therapeutics (NASDAQ: FATE) and sees high probability of positive data at ASH.
Peaker commented, "Fate provided a pipeline update on its 3Q15 call as well as an overview of its... More
Fate Therapeutics (FATE) Tops Q3 EPS by 6c
November 3, 2015 4:28 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1 million versus the consensus estimate of $430 thousand.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
... More